Skip to main content

In vitro pharmacology of clinically used central nervous system-active drugs as inverse H(1) receptor agonists.

Publication ,  Journal Article
Bakker, RA; Nicholas, MW; Smith, TT; Burstein, ES; Hacksell, U; Timmerman, H; Leurs, R; Brann, MR; Weiner, DM
Published in: J Pharmacol Exp Ther
July 2007

The human histamine H(1) receptor (H(1)R) is a prototypical G protein-coupled receptor and an important, well characterized target for the development of antagonists to treat allergic conditions. Many neuropsychiatric drugs are also known to potently antagonize this receptor, underlying aspects of their side effect profiles. We have used the cell-based receptor selection and amplification technology assay to further define the clinical pharmacology of the human H(1)R by evaluating >130 therapeutic and reference drugs for functional receptor activity. Based on this screen, we have reported on the identification of 8R-lisuride as a potent stereospecific partial H(1)R agonist (Mol Pharmacol 65:538-549, 2004). In contrast, herein we report on a large number of varied clinical and chemical classes of drugs that are active in the central nervous system that display potent H(1)R inverse agonist activity. Absolute and rank order of functional potency of these clinically relevant brain-penetrating drugs may possibly be used to predict aspects of their clinical profiles, including propensity for sedation.

Duke Scholars

Published In

J Pharmacol Exp Ther

DOI

ISSN

0022-3565

Publication Date

July 2007

Volume

322

Issue

1

Start / End Page

172 / 179

Location

United States

Related Subject Headings

  • Receptors, Histamine H1
  • Pyrilamine
  • Pharmacology & Pharmacy
  • NIH 3T3 Cells
  • Mice
  • Methylhistamines
  • Humans
  • Histamine H1 Antagonists
  • Histamine Agonists
  • Cloning, Molecular
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Bakker, R. A., Nicholas, M. W., Smith, T. T., Burstein, E. S., Hacksell, U., Timmerman, H., … Weiner, D. M. (2007). In vitro pharmacology of clinically used central nervous system-active drugs as inverse H(1) receptor agonists. J Pharmacol Exp Ther, 322(1), 172–179. https://doi.org/10.1124/jpet.106.118869
Bakker, R. A., M. W. Nicholas, T. T. Smith, E. S. Burstein, U. Hacksell, H. Timmerman, R. Leurs, M. R. Brann, and D. M. Weiner. “In vitro pharmacology of clinically used central nervous system-active drugs as inverse H(1) receptor agonists.J Pharmacol Exp Ther 322, no. 1 (July 2007): 172–79. https://doi.org/10.1124/jpet.106.118869.
Bakker RA, Nicholas MW, Smith TT, Burstein ES, Hacksell U, Timmerman H, et al. In vitro pharmacology of clinically used central nervous system-active drugs as inverse H(1) receptor agonists. J Pharmacol Exp Ther. 2007 Jul;322(1):172–9.
Bakker, R. A., et al. “In vitro pharmacology of clinically used central nervous system-active drugs as inverse H(1) receptor agonists.J Pharmacol Exp Ther, vol. 322, no. 1, July 2007, pp. 172–79. Pubmed, doi:10.1124/jpet.106.118869.
Bakker RA, Nicholas MW, Smith TT, Burstein ES, Hacksell U, Timmerman H, Leurs R, Brann MR, Weiner DM. In vitro pharmacology of clinically used central nervous system-active drugs as inverse H(1) receptor agonists. J Pharmacol Exp Ther. 2007 Jul;322(1):172–179.

Published In

J Pharmacol Exp Ther

DOI

ISSN

0022-3565

Publication Date

July 2007

Volume

322

Issue

1

Start / End Page

172 / 179

Location

United States

Related Subject Headings

  • Receptors, Histamine H1
  • Pyrilamine
  • Pharmacology & Pharmacy
  • NIH 3T3 Cells
  • Mice
  • Methylhistamines
  • Humans
  • Histamine H1 Antagonists
  • Histamine Agonists
  • Cloning, Molecular